Statin-use May Decrease Mortality Risk in Prostate Cancer
Patients who were diagnosed early on in the study, or who received endocrine therapy or radical prostatectomy, exhibited a lower HR for mortality vs other patients with PC.
Patients who take statins after prostate cancer (PC) diagnosis may have a reduced risk of mortality, according to a study published in the Journal of Clinical Oncology.1
The effect of statins on prostate cancer is complex, with laboratory evidence indicating that statins can have both pro- and anti-neoplastic effects, and previous studies yielding mixed results.
Study researchers accessed information from nationwide Danish registries and identified 31,790 men with prostate adenocarcinoma. Postdiagnosis statin-use was defined as filling at least 2 statin prescriptions, and patients who did not take statins prior to PC diagnosis were seen as nonusers until 1 year after the second statin prescription. Researchers also assessed the effects of pre-diagnosis statin-use as well as the effect of statin-use 1 year or 5 years after PC diagnosis.
At median follow-up of 2.8 years, 23% of patients had died from prostate cancer and 37% died of other causes. Patients who received postdiagnosis statins had a 17% lower risk of mortality vs nonusers (adjusted hazard ratio [AHR], 0.83; 95% CI, 0.77-0.89), and a similar effect was seen for all-cause mortality (AHR, 081; 95% CI, 0.76-0.85). Statin-use resulted in similar effects for the 1-year and 5-year sensitivity analyses. Pre-diagnosis statin-use showed no mortality benefit.
RELATED: Prostate Cancer: Metastasis-free Survival Is A Surrogate for OS
Patients who were diagnosed early on in the study, or who received endocrine therapy or radical prostatectomy, had a lower HR for mortality vs other patients with PC.
The authors concluded that “additional research is needed to establish whether statins have genuine therapeutic potential in the management of PC.”
- Larsen SB, Dehlendorff C, Skriver C, et al. Postdiagnosis statin use and mortality in Danish patients with prostate cancer. J Clin Oncol. 2017 Aug 14. doi: 10.1200/JOC.2016.71.8981 [Epub ahead of print]